Although the reduced body weight gain and serum triglyceride increase may partially contribute to the beneficial effects of Y20 in obesity cardiomyopathy, the beneficial actions of Y20 are closely associated with its ability to increase Nrf2 and inhibit NF-κB. The gene discussed is NFE2L2; the disease is cardiomyopathy.